# SIEMENS

## **Syva**<sup>®</sup>

# Emit<sup>®</sup> 2000 Vancomycin Assay

See shaded sections: Updated information from 2018-03 version.



10870285\_E



### Vancomycin Assay

#### 1 Intended Use

The Emit<sup>®</sup> 2000 Vancomycin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of vancomycin in human serum or plasma. Measurements obtained by this assay are used in the diagnosis and treatment of vancomycin overdose and in monitoring the level of vancomycin to ensure appropriate therapy.

#### 2 Summary and Explanation of the Test

Monitoring vancomycin concentrations in serum, along with careful clinical assessment, is the most effective means of ensuring adequate therapy for several reasons:

- Individual patients exhibit a high degree of variability in response to a given dose of vancomycin in terms of the volume of distribution and the rate of drug clearance from plasma.<sup>1</sup>
- The risk of ototoxicity and nephrotoxicity from vancomycin is increased in patients with impaired renal function and in patients receiving concurrent aminoglycoside therapy.<sup>1</sup>
- Patients with impaired renal or hepatic function, dialysis patients, morbidly obese patients, patients receiving concurrent aminoglycoside therapy, and pediatric or elderly patients should be monitored closely while on vancomycin therapy.<sup>1</sup>

Methods historically used to monitor serum vancomycin concentrations are microbiological assays, immunoassays, and chromatographic assays.<sup>1</sup>

#### 3 Principle

The Emit<sup>®</sup> 2000 Vancomycin Assay is a homogeneous enzyme immunoassay technique used for the quantitative analysis of vancomycin in human serum or plasma.<sup>2</sup> Serum or plasma is mixed with Reagent 1, which contains vancomycin labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Subsequently, Reagent 2, which contains antibodies to vancomycin and the coenzyme nicotinamide adenine dinucleotide (NAD), is added. Vancomycin in the sample and vancomycin-labeled G6PDH compete for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the vancomycin concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized NAD to NADH, resulting in an absorbance change that is measured spectrophotometrically. Endogenous G6PDH does not interfere because the coenzyme functions only with the bacterial (*Leuconostoc mesenteroides*) enzyme employed in the assay.

#### 4 Reagents

REF	Product Description	Quantity/Volume
4W019UL	Emit <sup>®</sup> 2000 Vancomycin Assay Enzyme Reagent 1 Vancomycin labeled with bacterial G6PDH (0.21 U/mL),* HEPES buffer, bovine serum albumin, preservatives, and stabilizers	28 mL
	Antibody/Substrate Reagent 2 Mouse monoclonal antibodies to vancomycin (27 µg/mL bovine serum albumin, G6P (44 mM), NAD (36 mM), preservatives, and stabilizers	14 mL ),*

\* The antibody titer and enzyme conjugate activity may vary from lot to lot.

Note: Reagents 1 and 2 are provided as a matched set. They should not be interchanged with components of kits with different lot numbers.

#### **Risk and Safety**

Safety data sheets (MSDS/SDS) available on siemens.com/healthcare

For in vitro diagnostic use.

#### Precautions

Reagents contain materials that may cause sensitivity on contact with skin. Wear suitable protective clothing and gloves.

#### Preparation and Storage of Assay Components

The Emit<sup>®</sup> 2000 Vancomycin Assay reagents are provided ready to use and may be used directly from the refrigerator. Close the reagent vials when not in use.

#### Note: Caps must always be replaced on the original containers.

When not in use, store reagents at 2–8°C (36–46°F), upright, and with the screw caps tightly closed. When stored as directed, reagents are stable until the expiration date printed on the label. Refer to the analyzer-specific application sheets for on-instrument stability information. Do not freeze reagents. Avoid prolonged exposure to temperatures above 32°C (90°F). **Improper storage of reagents can affect assay performance**.

#### 5 Specimen Collection and Preparation

- Each assay requires serum or plasma. Whole blood cannot be used. The anticoagulants EDTA, sodium heparin, citrate, and oxalate/fluoride have been tested and may be used with this assay. Some sample dilution may occur when samples are collected in tubes containing citrate anticoagulant. The amount of dilution and the possible need to correct for it should be considered when interpreting assay results for these samples.
- Sample volume is instrument-dependent. Refer to the appropriate analyzer-specific application sheet.
- Pharmacokinetic factors influence the correct time of sample collection after the last drug dose. These factors include dosage form, mode of administration, concomitant drug therapy, and biological variations affecting drug disposition.<sup>1</sup>
- To obtain a vancomycin concentration that best represents the peak tissue level, draw the sample 0.5–2 hours after an infusion.<sup>3</sup>
- To avoid in vitro degradation, store serum or plasma frozen at -20°C<sup>4</sup> or at -70°C if not analyzed immediately.
- Human serum or plasma samples should be handled and disposed of as if they were
  potentially infectious. It is recommended that human specimens be handled in accordance
  with the OSHA Standard on Bloodborne Pathogens or other appropriate local practices.<sup>5,6</sup>

#### 6 Procedure

#### **Materials Provided**

Emit<sup>®</sup> 2000 Vancomycin Assay

Reagent 1 Reagent 2

#### Materials Required But Not Provided

4W109UL Emit<sup>®</sup> 2000 Vancomycin Calibrators (0<sup>+</sup>, 5, 10, 20, 30, 50 μg/mL) \* Additional negative calibrator is provided.

#### Instruments

Siemens Healthcare Diagnostics provides instructions for using this assay on a number of chemistry analyzers.

Contact the Technical Assistance Center in the USA or your local Siemens representative for analyzer-specific application sheets.

Analyzers must be capable of maintaining a constant reaction temperature, pipetting specimens/ reagents and measuring enzyme rates precisely, timing the reaction accurately, and mixing reagents thoroughly.

#### Calibration

Recalibrate whenever a new <u>lot</u> of reagents is used or as indicated by control results (see Quality Control, below), using  $\operatorname{Emit}^{\textcircled{m}}$  2000 Vancomycin Calibrators (0–50 µg/mL). Refer to the instrument operator's manual for further instructions.

If a new set of reagents with the same lot number is used, validate the system by assaying controls.

#### **Quality Control**

- Validate the calibration by assaying multi-level controls. Commercial controls are available for this purpose. Ensure that control results fall within acceptable limits as defined by your own laboratory. Once the calibration is validated, run samples.
- Follow government regulations or accreditation requirements for quality control frequency. At least once each day of use, analyze two levels of a Quality Control (QC) material with known vancomycin concentrations. Follow your laboratory internal QC procedures if the results obtained are outside acceptable limits.
- 3. Refer to the instrument operator's manual for appropriate instrument checks.

#### **Diluting High-Concentration Samples**

To estimate vancomycin concentrations above the assay range, patient samples containing more than 50  $\mu$ g/mL (34  $\mu$ mol/L) vancomycin may be diluted with one or two parts of distilled or deionized water or Emit<sup>®</sup> 2000 Vancomycin Calibrator 0. After diluting the sample, test and multiply the results by the dilution factor.

#### 7 Results

Results are calculated automatically by the analyzers. No additional manipulation of data is required unless samples have been manually diluted.

This assay uses Math Model No.1.

Consult the appropriate instrument operating manual and analyzer-specific application sheet for complete instructions.

The factors that can influence the relationship between vancomycin serum or plasma concentrations and clinical response include the type and severity of infection, the susceptibility of the infecting organism to vancomycin, renal function, general state of health, and use of other drugs.<sup>1</sup>

The concentration of vancomycin in serum or plasma depends on the time of the last drug dose; mode of administration; concomitant drug therapy; sample condition; time of sample collection; and individual variations in absorption, distribution, biotransformation, and excretion. These parameters must be considered when interpreting results.<sup>1</sup>

For purposes of diagnosis and treatment, results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

#### 8 Limitations

- When diluting patient samples containing high vancomycin concentrations, the following factors can affect the accuracy of the result: diluting with the correct fluid (Emit<sup>®</sup> 2000 Vancomycin Calibrator 0 or distilled or deionized water) and the accuracy of the dilution.
- Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.
- Siemens has validated use of these reagents on various analyzers to optimize product
  performance and meet product specifications. User defined modifications are not supported
  by Siemens as they may affect performance of the system and assay results. It is the
  responsibility of the user to validate modifications to these instructions or use of the reagents
  on analyzers other than those included in Siemens Application Sheets or these instructions
  for use.

#### 9 Expected Values

The Emit<sup>®</sup> 2000 Vancomycin Assay accurately quantitates vancomycin concentrations in human serum or plasma containing 2.0–50  $\mu$ g/mL (1.3–34  $\mu$ mol/L) vancomycin.

Reported peak therapeutic ranges for vancomycin vary considerably. Both the dosage regimen and the timing of sample collection may affect the peak therapeutic range.<sup>1,3,7,8</sup> For example, after completion of a 60-minute infusion of vancomycin in adults, samples drawn at 2 hours had concentrations of 18–26 µg/mL (12–17 µmol/L),<sup>3</sup> samples drawn at 1 hour had concentrations of 26.5–40 µg/mL (18–27 µmol/L),<sup>8</sup> and samples drawn at 30 minutes had concentrations of 30–40 µg/mL (20–27 µmol/L).<sup>1,3</sup>

Trough vancomycin serum concentrations of 5.0–10 µg/mL (3.4–6.7 µmol/L) usually ensure that the concentration is above the minimum inhibitory concentrations of most vancomycin-sensitive pathogens and that the drug elimination is adequate  $^{1.7}$ 

For patients on concomitant vancomycin and aminoglycoside treatment, peak vancomycin concentrations exceeding 30  $\mu$ g/mL (20  $\mu$ mol/L) and trough concentrations above 10  $\mu$ g/mL (6.7  $\mu$ mol/L) are associated with nephrotoxicity.<sup>1</sup> Serum concentrations above 80  $\mu$ g/mL (54  $\mu$ mol/L) are associated with ototoxicity.<sup>1</sup>

#### Note: To convert from µg/mL to µmol/L vancomycin, multiply by 0.67.

For effective treatment, some patients may require serum or plasma levels outside these ranges. Therefore, the expected ranges are provided only as guidelines, and individual patient results should be interpreted in light of other clinical signs and symptoms.

#### **10** Specific Performance Characteristics

The data appearing in this section were collected on the SYVA®-30R Biochemical System.

The following performance characteristics represent total system performance and should not be interpreted to pertain only to reagents. Performance may vary depending on the instrumentation used.

#### Specificity

The Emit<sup>®</sup> 2000 Vancomycin Assay measures the total (protein-bound plus unbound) vancomycin concentration in serum or plasma. Compounds whose chemical structure or concurrent therapeutic use would suggest possible cross-reactivity have been tested.

The compounds listed in Table 1 do not interfere with the Emit<sup>®</sup> 2000 Vancomycin Assay when tested in the presence of 20  $\mu$ g/mL vancomycin. Levels tested were at or above maximum physiological or pharmacological concentrations.

#### Table 1 — Compounds That Do Not Interfere

	Concentration Tested	
Compound	(μg/mL)	
Acyclovir	25	
Amikacin	100	
Amphotericin B	20	
Aztreonam	200	
Caffeine	2	
CDP-1	20	
Cefazoline	500	
Cefotaxine	1000	
Chloramphenicol	100	
Ciprofloxicin	10	
Cisplatin	25	
Clindamycin	10	
Cyclosporine	50	
Digoxin	0.006	
Epinephrine	1	
Erythromycin	5	
Ethacrynic acid	50	
Flucytosine	100	
Furosemide	100	
Fusidic Acid	500	
Gentamicin	100	
Imipenem	70	
Methicillin	500	
Metronidazole	50	
Netilmicin	100	
Nitroprusside	60	
Penicillin G*	10	
Pentamidine	0.7	
Phenobarbital	40	
Rifampin	500	
Salicylate	60	
Sulphamethoxazole	600	
Theophylline	20	
Trimethoprim	25	
Tobramycin	100	

\*Approximately equivalent to 16.7 units/mL penicillin G.

For additional information, contact your Siemens representative.

#### Sensitivity

The sensitivity level of the Emit<sup>®</sup> 2000 Vancomycin Assay is 2.0 µg/mL vancomycin. This level represents the lowest concentration of vancomycin that can be distinguished from 0 µg/mL with a confidence level of 95%.

#### **Endogenous Substances**

No interference has been found in samples to which 20  $\mu$ g/mL vancomycin and either 800 mg/dL (8 g/L) hemoglobin or 30 mg/dL (0.3 g/L) free bilirubin were added to simulate hemolytic or icteric samples.

No interference has been found in lipemic patient samples containing 750 mg/dL (7.5 g/L) triglyceride to which 20  $\mu g/mL$  vancomycin was added.

#### **Calibration Stability**

Studies have shown calibration stability of at least 14 days. The quality control limits used in these studies were established by following the instructions in Section 6, Procedure, Quality Control. Calibration stability may vary from laboratory to laboratory depending on handling of reagents, maintenance of instruments, adherence to operating procedures, establishment of control limits, and verification of calibration.

#### Precision

Precision values were obtained using the SYVA®-30R Biochemical System. Precision was determined by measuring two replicates each of internal Siemens 3-level controls on 20 days with two runs per day. Precision was calculated according to National Committee for Clinical Laboratory Standards (NCCLS) Guideline EP5-A (February 1999). Results of these studies are summarized in Table 2.

#### Table 2 — Precision

Control	Number of	Mean	Standard	Coefficient of
	Replicates	(µg/mL)	Deviation (µg/mL)	Variation (%)
Within-Run				
1	80	7.4	0.3	4.2
2	80	17.5	0.4	2.4
3	80	34.0	1.5	4.6
Total				
1	80	7.4	0.4	4.9
2	80	17.5	0.6	3.5
3	80	34.0	1.9	5.7

#### **Method Comparison**

Patient samples with vancomycin concentrations ranging from 5 µg/mL to 50 µg/mL were analyzed by the Emit<sup>®</sup> 2000 Vancomycin Assay and by the Emit<sup>®</sup> Vancomycin Assay on the SYVA<sup>®</sup>-30R Biochemical System, and the results were compared. Data are summarized in Table 3.

#### Table 3 — Method Comparison

	Emit <sup>®</sup> 2000 vs Emit <sup>®</sup>
Slope	0.97
Intercept (µg/mL)	-0.24
Correlation Coefficient	0.97
Number of Samples	100

#### 11 Bibliography

- Rodvold KA, Erdman SM, Pryka RD: Vancomycin, in Schumacher GE (ed): Therapeutic Drug Monitoring. Norwalk, CT: Appleton and Lange; 1995:587–632.
- Hsu P, Ernst R, Levy M: Emit<sup>®</sup> 2000 tobramycin and vancomycin assays [abstract]. Clin Chem 2000; 46(suppl 6):page A195. Abstract 762.
- Fitzsimmons WE, Postelnick MJ, Tortorice PV: Survey of vancomycin monitoring guidelines in Illinois hospitals. *Drug Intell Clin Pharm*. 1988;22:598–600.
- Polk RE, Espinel-Ingroff A, Lockridge R: In vitro evaluation of a vancomycin radioimmunoassay and observations on vancomycin pharmacokinetics in dialysis patients. Drug Intell Clin Pharm. 1981;15:15–20.
- Occupational exposure to bloodborne pathogens (29 CFR 1910.1030). *Federal Register*. December 06, 1991;56:64004; amended April 13, 1992;57:12717; July 01, 1992;57:29206; February 13, 1996;61:5507.
- World Health Organization. Laboratory Biosafety Manual. 2nd ed. Geneva: World Health Organization; 1993.
- Moyer TP: Therapeutic drug monitoring, in Burtis CA, Ashwood ER (eds): *Tietz Textbook of Clinical Chemistry*. 3rd ed. Philadelphia, Pennsylvania: WB Saunders; 1999:886–905.
- Healy DP, Polk RE, Garson ML, Rock, DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. *Antimicrob Agents Chemother*. 1987;31(3):393–397.

#### 12 Symbols Key

2	Do not reuse / Nicht zur Wiederverwendung / Ne pas réutiliser / Non riutilizzare / No reutilizar
	Use By / Verwendbar bis / Utiliser jusque / Utilizzare entro / Fecha de caducidad
LOT	Batch Code / Chargenbezeichnung / Code du lot / Codice del lotto / Código de lote
REF	Catalogue Number / Bestellnummer / Référence du catalogue / Numero di catalogo / Número de catálogo
Â	Caution, consult accompanying documents / Achtung, Begleitdokumente beachten / Attention voir notice d'instructions / Attenzione, vedere le istruzioni per l'uso / Atención, ver instrucciones de uso
<b>666</b>	Manufacturer / Hersteller / Fabricant / Fabbricante / Fabricante
ECREP	Authorized Representative in the European Community / Bevollmächtigter in der Europäischen Gemeinschaft / Mandataire dans la Communauté europeenne / Mandatario nella Comunità Europea / Representante autorizado en la Comunidad Europea
$\nabla$	Contains sufficient for <n> tests / Inhalt ausreichend für <n> Tests / Contenu suffisant pour "n" tests / Contenuto sufficiente per "n" saggi / Contenido suficiente para <n> ensayos</n></n></n>
IVD	In Vitro Diagnostic Medical Device / In-Vitro-Diagnostikum / Dispositif médical de diagnostic in vitro / Dispositivo medico-diagnostico in vitro / Producto sanitario para diagnóstico in vitro
ľ	Temperature Limitation / Temperaturbegrenzung / Limites de température / Limiti di temperatura / Límite de temperatura
$\bigcap_{\wedge}$	Consult Instructions for Use / Gebrauchsanweisung beachten / Consulter les instructions d'utilisation / Consultare le istruzioni per l'uso / Consulte las instrucciones de uso
NON	Non-sterile / Nicht steril / Non stérile / Non sterile / No estéril
CE	CE Mark / CE Zeichen / Marquage CE / Marchio CE / Marca CE
CONTENTS	Contents / Inhalt / Contenu / Contenuto / Contenido
	Reconstitution Volume / Rekonstitutionsvolumen / Volume de reconstitution / Volume di ricostituzione / Volumen de reconstitución
LEVEL	Level / Konzentration / Niveau / Livello / Nivel
	2015-03_EFIGS

#### For technical assistance, call Siemens Healthcare Diagnostics: 1-800-227-8994 in the USA 1-800-264-0083 in Canada

Outside the USA and Canada, call your local Siemens representative.

Syva<sup>®</sup>, and Emit<sup>®</sup> are trademarks of Siemens Healthcare Diagnostics.

© 2011 Siemens Healthcare Diagnostics All rights reserved.

Siemens Healthcare Diagnostics Inc. 500 GBC Drive Newark, DE 19714 USA

Global Siemens Headquarters Siemens AG Wittelsbacherplatz 2 80333 Muenchen Germany

Global Siemens Healthcare Headquarters Siemens AG Healthcare Sector Henkestrasse 127 91052 Erlangen Germany Phone: +49 9131 84-0 siemens.com/healthcare Global Division Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, NY 10591 USA siemens.com/healthcare

Printed in USA 2019-07 10870285 US E